AERI Feb 2020 50.000 put

OPR - OPR Delayed Price. Currency in USD
26.25
0.00 (0.00%)
As of 11:56AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close26.25
Open26.25
Bid29.00
Ask30.50
Strike50.00
Expire Date2020-02-21
Day's Range26.25 - 26.25
Contract RangeN/A
Volume3
Open InterestN/A
  • Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue?
    Zacks

    Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ?
    Insider Monkey

    Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • Business Wire

    Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Should the MAA for Roclanda® be accepted for review by the EMA, an opinion from the Committee for Medicinal Products for Human Use is expected in approximately 12 months.

  • Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • 5 “Strong Buy” Biotech Stocks With More Than 80% Upside
    InvestorPlace

    5 “Strong Buy” Biotech Stocks With More Than 80% Upside

    For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry. Unlike companies that build up their businesses over time at a steadier pace, biotechs rely on just a few studies or trials of their therapies. As a result, favorable outcomes can catapult share prices upwards. An upset, however, can have the opposite effect.This is why it's essential to do your homework before investing in these often difficult-to-gauge stocks. That's where TipRanks.com comes in. Using the platform, I was able to get access to a host of in-depth market data to help me pinpoint the most compelling investment opportunities in the biotech space.To this end, I found not one, not two, but five biotech stocks poised for huge gains in the long-run. I'm not kidding when I say "huge." I'm referring to more than 80% upside potential from the current share price. Not to mention each has received enough bullish recommendations in the last three months to earn a "strong buy" consensus rating.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy in December Here's the play-by-play. Akebia Therapeutics (AKBA)Source: Shutterstock About 37 million people in the U.S. are affected by chronic kidney disease (CKD). With its commercially available drug, Auryxia, and its other candidate, Vadadustat, in global Phase 3 clinical development, Akebia Therapeutics (NASDAQ:AKBA) wants to provide new treatment options for patients suffering from the disease.While Auryxia sales in its most recent quarter have posed a cause for concern, Piper Jaffray analyst Christopher Raymond is staying onboard. During its third quarter, Auryxia sales came in at $30 million, $2 million less than the five-star analyst estimated. While definitely not the ideal result, the fact of the matter remains that Auryxia has a more important role as a vehicle for Akebia to establish a commercial platform from which to release the "real value driver - Vadadustat."With respect to AKBA's Vadadustat program, both the INNO2VATE and PRO2TECT studies are fully enrolled, meaning that it is on track to report top-line data in Q2 of 2020 and mid-2020, respectively. In two of the drug's Phase 3 pivotal studies conducted by its collaboration partner in Japan, MTPC, data showed that Vadadustat's effect on hemoglobin was sustained in patients with anemia due to CKD, a positive result in terms of efficacy.Bearing this in mind, Raymond maintained his bullish thesis but did reduce the price target from $22 to $15. Despite this drop, this target implies that shares could soar 208% over the next twelve months.Like Raymond, the rest of the Street is betting on this biotech stock. As four "buy" ratings have been assigned in the last three months compared to no "holds" or "sells," the consensus is unanimous: AKBA is a "strong buy." In addition, the $16 average price target indicates 218% upside potential. See the AKBA stock analysis. Aerie Pharmaceuticals (AERI)Source: Shutterstock Aerie Pharmaceuticals (NASDAQ:AERI) is an ophthalmic pharmaceutical company developing innovative treatments for patients with glaucoma and retinal diseases. Despite the major hit shares have taken year-to-date, some analysts argue that AERI is under-appreciated on Wall Street.Part of the problem stems from the company's performance in its most recent quarter. Not only did AERI post an earnings miss, but it also cut its 2019 sales guidance for the second consecutive quarter.However, according to Piper Jaffray's Joseph Catanzaro, there is a positive takeaway from all this. He tells investors that management's outlook for the short-term has become much more "realistic." The analyst adds that he sees little evidence to demonstrate that there has been a reversal in quarterly script trends observed for Rhopressa and Rocklatan, its glaucoma drugs.As a result, Catanzaro kept his "overweight" rating while lowering the price target from $53 to $48. Still, this target conveys his confidence in AERI's ability to climb 159% higher in the next twelve months. * 7 Stocks to Buy With Great Charts All in all, other Wall Street analysts take a similar approach when it comes to AERI. Based on the seven "buys" and no "holds" or "sells" received in the last three months, the bulls have it and the consensus is that the stock is a "strong buy." On top of this, its $42 average price target puts the potential twelve-month gain at 129%. See the AERI stock analysis. Cytokinetics (CYTK)Source: Shutterstock A leader in muscle biology research, Cytokinetics, Inc. (NASDAQ:CYTK) specializes in muscle activators and muscle inhibitors to treat conditions and diseases characterized by muscle weakness, fatigue or diminished muscle function. On the heels of promising new data presented by the company, investor focus has locked in on this biotech.Investors got some good news back in September when CYTK presented data from the Phase 1 study of its CK-274 drug in healthy patients at the annual Heart Failure Society of America (HFSA) meeting. As these results indicated favorable findings in terms of safety and tolerability, CYTK can move forward with its Phase 2 clinical trial to evaluate the drug's effectiveness in patients with obstructive hypertrophic cardiomyopathy (HCM). HCM is an inherited condition that causes part of the heart to get thicker, affecting its ability to pump blood. Given the limited available options in terms of treating heart failure, the drug's implications could fuel massive growth.This outcome prompted a wave of bullish calls to be published, five to be exact. Based on the 100% Street support, the message is clear: CYTK is a "strong buy." Not to mention its $23 average price target suggests there's room for 146% upside from the current share price.One of the analysts singing the biotech's praises is H.C. Wainwright's Joseph Pantginis. Along with his recent "buy" rating, the analyst set a $30 price target, the highest out of the analysts covering the name in the last three months. This means he sees a whopping 216% potential twelve-month gain in store. See the CYTK stock analysis. Novavax (NVAX)Source: Shutterstock Yes, Novavax (NASDAQ:NVAX) is definitely down, but don't count this biotech out just yet. The company, which is best known for producing vaccine candidates, is completely surrounded by bulls. I mean to say that all of the analysts that have covered the stock in the last three months issued a "buy" recommendation, which could be a signal that something positive is around the corner.Oppenheimer analyst Kevin DeGeeter believes that this is in fact the case in spite of the recent headwind it faced. After the company filed an 8-K disclosing that the EMA declined to support use of the conditional marketing authorization pathway for approval of ResVax, its aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine, in the EU, approval without another clinical trial seems unlikely.However, DeGeeter reminds investors that he is expecting a positive Phase 3 outcome for NanoFlu in the first quarter of 2020. He argues that this could be a potential catalyst for shares. As a result, he remains optimistic about NVAX.In just the past week, H.C. Wainwright's Vernon Bernardino also decided to stay on board. Along with his bullish call, the $17 price target indicates shares could jump a whopping 350% in the next twelve months. * 7 of the Best Internet Stocks to Buy While Bernardino's forecast implies huge upside potential, based on the $23 average price target the Street sees even more. We're talking 512% here. See the NVAX stock analysis. Translate Bio (TBIO)Source: Shutterstock Translate Bio (NASDAQ:TBIO) is pioneering a new approach to treating disease with messenger RNA, with its lead candidate in development for the treatment of cystic fibrosis (CF), a hereditary disease impacting the lungs and digestive system. With the disease affecting 30,000 people in the U.S., there's a huge unmet need.The company has found itself in hot water recently following its decision to terminate its preclinical OTC deficiency program to treat liver disease based on disappointing data."We believe that the success to date in our cystic fibrosis program positions us well to build on our lung delivery platform and maximize the potential of our mRNA technology in additional pulmonary diseases with unmet medical need," CEO Ronald Renaud stated.While this took a toll on shares, Leerink Partners analyst Geoff Porges argues that he views this news as a positive. "It is encouraging to see TBIO commit to this platform and the CF program and is consistent with the groundbreaking potential of its lung LNP delivery system. The decision to abandon the OTCD program was probably relatively easy given the challenges associated with that indication for TBIO and other developers," he noted. To this end, he maintained his bullish call and $20 price target, putting the upside potential at 98%.With 100% Street support, the word on the Street is that TBIO is a "strong buy." Additionally, its $18 average price target suggests a potential twelve-month gain of 81%. See the TBIO stock analysis.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Maya Sasson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy in December * 7 Unsteady Stocks Investors Should Consider Selling Before 2020 * 7 Entertainment Stocks to Buy to Escape Holiday Blues The post 5 a€œStrong Buya€ Biotech Stocks With More Than 80% Upside appeared first on InvestorPlace.

  • TEST Business Wire Releases

    Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:00 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and provide a business update.

  • Benzinga

    The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • Business Wire

    Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Commission (EC) has granted a marketing authorisation for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.

  • Aerie buys Spanish outfit as it moves toward profitability
    American City Business Journals

    Aerie buys Spanish outfit as it moves toward profitability

    Looking beyond its immediate path to profitability, a Triangle drugmaker has acquired a company in order to expand its product pipeline.

  • Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
    Zacks

    Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex

    Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

  • Business Wire

    Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program

    Company Plans to Commence Phase 2b Study in Dry Eye Subjects in Late 2020

  • Business Wire

    Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Thomson Reuters StreetEvents

    Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT

    Q3 2019 Aerie Pharmaceuticals Inc Earnings Call

  • Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
    Zacks

    Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed

    Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

  • Benzinga

    The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...

  • Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of -2.38% and 5.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today reported positive topline results for the Company’s Phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork, the eye’s primary drainage pathway. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Business Wire

    Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its third quarter 2019 financial results will be released after the market closes on Wednesday, November 6, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com.

  • Business Wire

    Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., Ph.D., Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on November 11, 2019 and will direct the Company’s preclinical and clinical research and development groups, as well as medical and professional affairs.

  • Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
    Zacks

    Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ?

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]

  • Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62%
    Simply Wall St.

    Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62%

    The nature of investing is that you win some, and you lose some. And there's no doubt that Aerie Pharmaceuticals, Inc...

  • Business Wire

    Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that patient enrollment in its Phase 2 clinical trial of AR-1105 in patients with macular edema due to retinal vein occlusion (RVO) is complete several weeks ahead of schedule. AR-1105 is an investigational sustained-release, bio-erodible intravitreal implant containing dexamethasone. The Phase 2 study (AR-1105-CS201), conducted at 19 centers in the United States, had an enrollment target of 45 patients.